Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
|Articles|May 23, 2022
This week on Contemporary OBGYN®: May 23 to May 27
Author(s)Lindsey Carr, Editor
Coming up on Contemporary OBGYN®
Advertisement
Coronavirus Omicron variant, vaccine, and case numbers in the United States: May 23, 2022
How many novel coronavirus (COVID-19) cases were announced today?
Health care systems start program to ensure equity in patient care
AMA, Joint Commission aim to improve outcomes for marginalized patients.
Check back soon for additional highlights.
Advertisement
Related to this article
Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Neurokinin receptor antagonists improve menopausal sleep disturbance
2
Stephanie Faubion, MD, on the first menopause therapy discussion
3
Red flags that point beyond menopause in patients with night sweats
4
How misread WHI data reshaped menopause care and training
5